A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Eisai Inc.
Study ID
NCT07308236
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • E2086 — DRUG
    E2086 oral capsule.

Study Details

The primary purpose of this study is to determine the metabolism and excretion of \[14C\]E2086 in healthy male participants.

Key Dates

Start date
Dec 31, 2025
Status verified
Dec 2025
Primary completion
Feb 23, 2026
Completion
Feb 23, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: E2086

Primary Outcome Measure

Mass Balance Recovery of E2086, Expressed as Cumulative Percent of the Radiolabeled Dose [ Time Frame: Day 1 up to Day 21 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Inc.MadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Inc.· Madison, WI

Related Studies